View source for Acrivastine

 {{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477241254
| IUPAC_name = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| image =Acrivastine.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|acrivastine}}
| MedlinePlus = a682619
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| routes_of_administration = oral

<!--Pharmacokinetic data-->
| elimination_half-life = 1.5 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 87848-99-5
| ATC_prefix = R06
| ATC_suffix = AX18
| PubChem = 5284514
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447574
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A20F9XAI7W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02760
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1224
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 83168

<!--Chemical data-->
| C=22 | H=24 | N=2 | O=2 
| molecular_weight = 348.438 g/mol
| smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3
| InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| InChIKey = PWACSDKDOHSSQD-IUTFFREVBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N
}}
__Notoc__
{{SI}}
{{CMG}}
==Overview==
'''Acrivastine''' is a medication used for the treatment of allergies and [[hay fever]]. It is a second-generation [[H1 antagonist|H1-receptor antagonist]] [[antihistamine]] (like its base molecule [[triprolidine]]) and works by blocking [[Histamine H1 receptor]]s.

This non-sedating{{verify source|date=November 2014}} antihistamine is sold under the brand name Benadryl Allergy Relief in the [[United Kingdom]] by [[McNeil Laboratories]], not to be confused with Benadryl Once a Day, which is [[cetirizine]] and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a [[decongestant]], [[pseudoephedrine]]. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.<ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7627 SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule] U.S. [[National Library of Medicine]], National Institutes of Health, May 2008</ref>

==Comparisons with other popular antihistamines==
Unlike [[cetirizine]] or [[loratadine]], the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.<ref>{{cite web |url=http://www.medicines.org.uk/EMC/pdfviewer.aspx?isAttachment=true&documentid=21852 |title=Benadryl Allergy Relief |work=electronic Medicines Compendium (eMC) |year=2014 |accessdate=4 July 2014}}</ref> Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.

==References==
{{reflist|2}}

{{Antihistamines}}
{{Histaminergics}}

[[Category:H1 receptor antagonists]]
[[Category:Pyridines]]
[[Category:Pyrrolidines]]
[[Category:Alkenes]]
[[Category:Drug]]